Gastrointestinal · Investigational
Gastrin
No lawful US pathway
01 · Overview
Gastrin is a peptide hormone made mainly in antroduodenal G-cells, with gastrin-34 and gastrin-17 as the major forms in tissue and plasma (PMID 17584137). It acts on the CCK2 (gastrin/CCK-B) receptor to regulate gastric acid secretion and to promote growth of the gastric mucosa and enterochromaffin-like cells (PMID 17415644).
Therapeutic interest has focused on diagnostic acid-secretion testing and on blocking gastrin in gastrin-sensitive tumors. Chronic excess gastrin occurs in Zollinger-Ellison syndrome and pernicious anemia (PMID 17415644).
02 · Research summary & key findings
In healthy volunteers, infusion of synthetic human gastrin-17 increased gastric acid secretion, an effect blocked by an H2-receptor antagonist, indicating that histamine mediates much of gastrin action in humans (PMID 8105512). Pentagastrin, a short synthetic gastrin analogue, is still used to stimulate acid secretion in clinical pharmacology studies (PMID 25335860). The anti-gastrin immunogen G17DT reached phase 3 trials in advanced pancreatic cancer, with a survival benefit versus placebo in one trial but no overall survival benefit when combined with gemcitabine in another (PMID 17309331). No gastrin-based therapy has been approved.
03 · Regulatory status
Gastrin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Gastrin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.
See the 7 FDA-approved compounds in Gastrointestinal
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
04 · Administration routes
- Subcutaneous injection
- Intravenous
References
- [1]G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy Expert Opin Biol Ther, 2007. PMID 17309331
- [2]Chronic hypergastrinemia: causes and consequences Dig Dis Sci, 2007. PMID 17415644
- [3]The biology of cholecystokinin and gastrin peptides Curr Top Med Chem, 2007. PMID 17584137
- [4]Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects Br J Clin Pharmacol, 2015. PMID 25335860
- [5]In man histamine and muscarinergic mechanisms are essential mediators of acid secretion in response to synthetic human gastrin (1-17) Regul Pept, 1993. PMID 8105512
Primary literature
- PubMed: "Gastrin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Gastrin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Gastrin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Gastrointestinal
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.